TYK2 and psoriasis: TYK2 inhibitors in phase II development for psoriasis include ESK-001 (Alumis, Inc., San Francisco, CA, USA) and BMS-986322 (Bristol Myer’s Squib, New York, NY, USA), a structural variant of deucravacitinib (Table 1).